New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases-Reference-Cited by-同舟云学术

New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases

Published:2007-10 Issue:10 Volume:3 Page:570-579
ISSN:1745-8382
Container-title:Nature Clinical Practice Rheumatology
language:en
Short-container-title:Nat Rev Rheumatol

Author:

Yacoubian Stephanie,Serhan Charles N

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

http://www.nature.com/articles/ncprheum0616.pdf

Reference67 articles.

1. Samuelsson B et al. (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237: 1171–1176

2. Vane JR (1982) Adventures and excursions in bioassay: the stepping stones to prostacyclin. In Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures, 181–206. Stockholm: Almqvist & Wiksell

3. Serhan CN and Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6: 1191–1197

4. Maddox JF and Serhan CN (1996) Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med 183: 137–146

5. Levy BD et al. (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2: 612–619

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Infections, SARS-CoV-2 Infection, and Autoimmunity;Infection and Autoimmunity;2024

2. From Inflammation to Resolution: Specialized Pro-resolving Mediators in Posttraumatic Osteoarthritis;Current Osteoporosis Reports;2023-08-24

3. Addition of Resolvins D1 or E1 to Collagen Membranes Mitigates Their Resorption in Diabetic Rats;Journal of Functional Biomaterials;2023-05-19

4. Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren’s syndrome;Frontiers in Immunology;2023-01-12

5. Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study;BMJ Neurology Open;2022-11